This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Roy M. Gulick, MD; Margo Heath-Chiozzi, MD; Clyde S. Crumpacker, MD

Arch Dermatol. 1990;126(8):1086-1088.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Contact with varicella-zoster virus (VZV) is nearly universal in the United States, manifesting disease as varicella (primary infection) and herpes zoster (secondary or reactivated infection). Greater than 90% of adults in the United States show serologic evidence of previous VZV exposure. Prior to the acquired immunodeficiency syndrome (AIDS), there were an estimated three million cases of varicella and 1.5 million cases of zoster occurring annually in the United States. In 1983, VZV disease was first recognized in the context of infection with the human immunodeficiency virus (HIV). Since that time, there have been many reports on the occurrence and clinical manifestations of herpes zoster in HIV-infected patients and, more recently, the occurrence of primary varicella in such patients. In this issue of the ARCHIVES,^1-3 three reports describe various aspects of VZV disease in the context of HIV infection.

Prior to AIDS, the annual incidence of herpes zoster in the general population was about . . . [Full Text PDF of this Article]

Author Affiliations
Department of Infectious Diseases Beth Israel Hospital 330 Brookline Ave/Dana 617 Boston, MA 02215

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?